secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001140361-25-026853
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics partners with Global RDH12 Alliance for OPGx-RDH12; $1.6M funding
-------------------------------------------------------------------------------

- Agreement with RDH12 Fund for Sight and Eyes on the Future provides up to $1.6M for OPGx-RDH12 development.
- Partnership includes risk-sharing structure and performance-based milestones; IND filing targeted by late 2025.
- If milestones missed, Funding Parties can exercise a non-exclusive license; Opus retains right to negotiate exclusive license back.
- During term, Opus cannot grant exclusive U.S. license to a third party without Funding Parties' consent.
- Term ends upon dosing three patients in Phase 1a/2b or first commercial sale, or if exclusive global licensee assumes obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125026853/0001140361-25-026853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125026853/ef20052404_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-026853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer